0.5417
Schlusskurs vom Vortag:
$0.601
Offen:
$0.5254
24-Stunden-Volumen:
1.49M
Relative Volume:
1.58
Marktkapitalisierung:
$30.23M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-151.16M
KGV:
-0.1824
EPS:
-2.97
Netto-Cashflow:
$-130.08M
1W Leistung:
-1.51%
1M Leistung:
-24.47%
6M Leistung:
-63.15%
1J Leistung:
-96.79%
Alx Oncology Holdings Inc Stock (ALXO) Company Profile
Firmenname
Alx Oncology Holdings Inc
Sektor
Branche
Telefon
650-466-7125
Adresse
323 ALLERTON AVENUE, SOUTH SAN FRANCISCO
Vergleichen Sie ALXO mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
ALXO
Alx Oncology Holdings Inc
|
0.5417 | 30.23M | 0 | -151.16M | -130.08M | -2.97 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
493.84 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
602.64 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
614.76 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
251.56 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
244.90 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Alx Oncology Holdings Inc Stock (ALXO) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-03-06 | Hochstufung | Jefferies | Hold → Buy |
2024-12-19 | Herabstufung | Jefferies | Buy → Hold |
2024-03-08 | Herabstufung | Stifel | Buy → Hold |
2023-12-08 | Hochstufung | Jefferies | Hold → Buy |
2021-12-22 | Herabstufung | Jefferies | Buy → Hold |
2021-09-30 | Eingeleitet | Stifel | Buy |
2021-05-05 | Fortgesetzt | Credit Suisse | Outperform |
2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
2021-04-06 | Eingeleitet | UBS | Buy |
2021-02-10 | Eingeleitet | H.C. Wainwright | Buy |
2020-08-11 | Eingeleitet | Cantor Fitzgerald | Overweight |
2020-08-11 | Eingeleitet | Credit Suisse | Outperform |
2020-08-11 | Eingeleitet | Jefferies | Buy |
2020-08-11 | Eingeleitet | Piper Sandler | Overweight |
Alle ansehen
Alx Oncology Holdings Inc Aktie (ALXO) Neueste Nachrichten
ALX Oncology’s CD47-blocker and Keytruda combo fails in two Phase II trials - Yahoo Finance
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Receives Consensus Recommendation of “Moderate Buy” from Brokerages - Defense World
ALX Oncology faces Nasdaq delisting over price rule - Investing.com Australia
ALX Oncology (ALXO) Stock Dips After Phase 2 Trial Setback - GuruFocus
Evorpacept fails to meet trial endpoints in HNSCC - Investing.com
ALX Oncology faces Nasdaq delisting over price rule By Investing.com - Investing.com South Africa
ALX Oncology Announces Encouraging Final Results from Phase 1 Tr - GuruFocus
Sector Update: Health Care - marketscreener.com
Alx Oncology Holdings Inc: Rising -96.84% from 52-Week Low, Can the Stock Stay Afloat? - investchronicle.com
ALX Oncology (ALXO) Reports Promising Phase 1 Trial Results for Evorpacept in B-Cell Lymphoma | ALXO Stock News - GuruFocus
Evorpacept fails to meet trial endpoints in HNSCC By Investing.com - Investing.com South Africa
ALX Oncology Phase 1/2 Evorpacept Trial to Treat B-cell Non-Hodgkin Lymphoma Shows Anti-tumor Activity - marketscreener.com
ALX Oncology Reports Promising Phase 1 Results for Evorpacept in Combination with Rituximab and Lenalidomide in B-cell Non-Hodgkin Lymphoma at AACR 2025 - Nasdaq
ALX Oncology Announces Encouraging Final Results from Phase 1 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with B-cell Non-Hodgkin Lymphoma - GlobeNewswire
Breakthrough: New Lymphoma Treatment Achieves 83% Complete Response Rate, Outperforming Standard Therapy - Stock Titan
ALX Oncology stock falls on trial setback (ALXO:NASDAQ) - Seeking Alpha
ALX Oncology's Phase 2 Trials In Head & Neck Cancer Fail To Meet Primary Endpoints - Nasdaq
ALX Oncology's Phase 2 Trials of Evorpacept, Keytruda Combination in Head, Neck Cancers Fail to Meet Primary Endpoints - marketscreener.com
ALX Oncology Reports ASPEN-03 and ASPEN-04 Phase 2 Trials Evalua - GuruFocus
ALX Oncology (ALXO) Shares Update After Phase 2 Trials Yield Mixed Results | ALXO Stock News - GuruFocus
ALX Oncology Reports ASPEN-03 and ASPEN-04 Phase 2 Trials - GlobeNewswire
ALX Oncology's Evorpacept Falls Short in Dual Phase 2 Head and Neck Cancer TrialsWhat's Next? - Stock Titan
Sei Investments Co. Makes New Investment in ALX Oncology Holdings Inc. (NASDAQ:ALXO) - Defense World
ALXO stock plunges to 52-week low of $0.48 amid market challenges - Investing.com India
ALXO stock plunges to 52-week low of $0.48 amid market challenges By Investing.com - Investing.com South Africa
ALX Oncology advances new cancer drug into Phase 1 trials By Investing.com - Investing.com South Africa
ALX Oncology Receives IND Clearance from U.S. FDA for ALX2004, a Novel EGFR-targeted Antibody-drug Conjugate - GlobeNewswire
ALX Oncology gets FDA nod to begin trial of ALX2004 (ALXO) - Seeking Alpha
FDA clears ALX Oncology’s IND for ALX-2004 - BioWorld MedTech
Alx Oncology Receives Ind Clearance From U.S. FDA For Alx2004 - marketscreener.com
ALX Oncology advances new cancer drug into Phase 1 trials - Investing.com
Breakthrough Cancer Drug Gets FDA Green Light: ALX2004 Targets Multiple Solid Tumors - Stock Titan
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
ALXO stock touches 52-week low at $0.65 amid market challenges - Investing.com Australia
Cantor Fitzgerald Raises Earnings Estimates for ALX Oncology - Defense World
ALXO stock plunges to 52-week low of $0.73 amid market challenges - Investing.com Australia
ALXO stock plunges to 52-week low of $0.73 amid market challenges By Investing.com - Investing.com South Africa
ALX Oncology Holdings (ALXO) Could Find a Support Soon, Here's Why You Should Buy the Stock Now - Yahoo
Why ALX Oncology Holdings Inc. (ALXO) Soared on Thursday - MSN
ALXO stock touches 52-week low at $0.89 amid market challenges - Investing.com Australia
ALXO stock touches 52-week low at $0.89 amid market challenges By Investing.com - Investing.com South Africa
Insider Buying: Rekha Hemrajani Acquires 30,000 Shares of ALX On - GuruFocus.com
ALX Oncology Holdings: Balancing Growth Potential and Uncertainty with a Hold Rating - TipRanks
Stifel Nicolaus Lowers ALX Oncology (NASDAQ:ALXO) Price Target to $1.50 - Defense World
ALX Oncology (NASDAQ:ALXO) Earns “Buy” Rating from HC Wainwright - Defense World
Finanzdaten der Alx Oncology Holdings Inc-Aktie (ALXO)
Umsatz
Nettogewinn
Free Cashflow
ENV
Alx Oncology Holdings Inc-Aktie (ALXO) Insiderhandel
Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
---|---|---|---|---|---|---|---|
Pons Jaume | PRESIDENT & CSO |
Feb 19 '25 |
Sale |
1.15 |
1,326 |
1,525 |
579,388 |
Lettmann Jason | CHIEF EXECUTIVE OFFICER |
Feb 19 '25 |
Sale |
1.15 |
2,159 |
2,483 |
170,270 |
Pinto Shelly | Interim CFO |
Jan 06 '25 |
Sale |
1.80 |
2,221 |
3,998 |
87,902 |
Pinto Shelly | Interim CFO |
Dec 30 '24 |
Sale |
1.58 |
1,426 |
2,253 |
90,123 |
Pons Jaume | PRESIDENT & CSO |
Dec 30 '24 |
Sale |
1.58 |
10,796 |
17,060 |
580,714 |
Hemrajani Rekha | Director |
Dec 02 '24 |
Buy |
1.55 |
30,000 |
46,404 |
33,000 |
Pinto Shelly | SVP, FINANCE AND CAO |
Aug 14 '24 |
Sale |
2.58 |
564 |
1,455 |
91,549 |
Randolph Sophia | CHIEF MEDICAL OFFICER |
Aug 14 '24 |
Sale |
2.58 |
1,365 |
3,522 |
325,711 |
Pons Jaume | PRESIDENT & CSO |
Aug 14 '24 |
Sale |
2.58 |
1,937 |
4,997 |
591,510 |
Pons Jaume | PRESIDENT & CSO |
Jul 11 '24 |
Option Exercise |
0.99 |
20,000 |
19,800 |
613,447 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):